Skip to main content

Table 10 Tissue silver content after 90-day oral administration of silver nanoparticles

From: Subchronic oral toxicity of silver nanoparticles

Silver (μg/g wet weight)

Dose/Sex

Testes

Liver

Kidneys

Brain

Lungs

Blood

0 mg/Kg

      

Male

0.04 ± 0.02

0.02 ± 0.01

0.04 ± 0.02

0.02 ± 0.01 a

0.10 ± 0.08

0.001 ± 0.000

Female

 

0.01 ± 0.01

0.03 ± 0.01

0.01 ± 0.01 a

0.05 ± 0.02

0.002 ± 0.002

30 mg/Kg

      

Male

6.56 ± 0.33**

4.20 ± 1.57** a

1.49 ± 0.37** b

0.47 ± 0.18**

1.94 ± 0.64** b

0.111 ± 0.016**

Female

 

8.56 ± 3.22** a

7.98 ± 0.91** b

0.38 ± 0.05**

4.97 ± 0.90 b

0.087 ± 0.017**

125 mg/Kg

      

Male

11.84 ± 1.62**

10.19 ± 2.09** b

8.82 ± 2.13** b

0.69 ± 0.06**

10.97 ± 3.81**

0.191 ± 0.037** b

Female

 

29.13 ± 9.74** b

37.09 ± 17.44** b

0.77 ± 0.11**

17.64 ± 9.06**

0.122 ± 0.010** b

500 mg/Kg

      

Male

23.75 ± 9.13**

68.65 ± 33.59**

99.19 ± 32.82** b

3.54 ± 1.44**

56.04 ± 51.14

0.419 ± 0.083**

Female

 

98.75 ± 31.65**

226.88 ± 55.64** b

3.70 ± 1.17**

45.83 ± 11.43**

0.303 ± 0.099**

  1. **Significant difference vs. control, p < 0.01. (ANOVA)
  2. a Significant difference vs. distinction of sex, p < 0.05. (T-test)
  3. b Significant difference vs. distinction of sex, p < 0.01. (T-test)